Metabolite Profiling of Blood From Individuals Undergoing Planned Myocardial Infarction Reveals early Markers of Myocardial Injury
News Sep 12, 2008
Normally, it takes up to six hours to diagnose a heart attack with certainty. The new approach can do so in just 10 minutes. Alterations in levels of multiple metabolites were detected as early as 10 minutes after PMI in an initial derivation group and were validated in a second, independent group of PMI patients. A PMI-derived metabolic signature consisting of aconitic acid, hypoxanthine, trimethylamine N-oxide, and threonine differentiated patients with SMI from those undergoing diagnostic coronary angiography with high accuracy, and coronary sinus sampling distinguished cardiac-derived from peripheral metabolic changes.
"Interventions are most effective in the first few hours, and their effectiveness falls off with time," says Robert Gerszten, director of translation research in the cardiology division of Massachusetts General Hospital, in Boston, who led development of the new test. "Time equals injury."
Diagnosis normally involves a physical examination, an electrocardiogram, and blood tests that look for key metabolites, including the protein complex troponin. However, this can take many hours: troponin is an indication of cardiac damage and therefore does not show up until hours after an attack. Once a heart attack has been confirmed, a patient can be given more-effective treatments such as beta blockers and anticoagulation drugs. But it is important to get the diagnosis right, as treating someone for a heart attack when he hasn't had one can cause further health complications, says Andrew Grace, a cardiologist at Papworth Hospital, in Cambridge, U.K. "There are all kinds of long-term implications in terms of insurance and the patient's state of mind that require [accurate] diagnosis," Grace adds.
There has already been a lot of interest in using metabolic profiling to diagnose disease, says Gerszten. But it can be problematic because metabolites vary significantly from one individual to another, and even within the same person, depending on what he or she has eaten.
To address this issue, Gerszten and his colleagues took advantage of a treatment administered for a heart condition called hypertrophic cardiomyopathy. "Patients with hypertrophic cardiomyopathy actually benefit from a planned heart attack," says Gerszten. The treatment involves injecting alcohol into part of the heart to cause a small, controlled heart attack that destroys excess tissue that is causing problems.
This setup also provides a unique opportunity to detect the metabolites related to heart attacks. By taking blood samples from 36 patients before and after they underwent the procedure, Gerszten's team was able to screen out background metabolites and determine exactly which ones emerged directly after the attack.
Each patient's blood was analyzed using a mass spectrometer and a technique known as multiplexing, which allows a large number of metabolites to be screened almost simultaneously. Within 10 minutes, the blood was analyzed for 210 metabolites, and the results were compared with those found in the blood before the heart attack. "It's a subtractive analysis," says Gerszten. "That's the beauty of this setup: each person is their own biological control."
Data gathered from 20 of the patients provided a signature of several dozen metabolites. This signature was then validated against the remaining 16 patients, as well as against an additional 12 ER patients who had suffered spontaneous heart attacks. Gerszten's team found that the signature could be used to identify heart attacks with an accuracy of greater than 80 percent. The results of his study are published in the Journal of Clinical Investigation.
Gerszten plans to extend his research to include many more patients. If precursor biomarkers can be identified, the hope is that this sort of technique could ultimately be used to predict heart attacks, and hence possibly even avert them.
Original Articel: Lewis GD et al Journal of Clinical Investigation 2008 doi:10.1172/JCI35111
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE